View in EDS HTML Full Text PDF Full Text

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Saved in:
Bibliographic Details
Title: Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Authors: Ferguson M; Colchester Research Group, Truro, Canada., Schwarz TF; Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany., Núñez SA; Centro Medico Maffei, Buenos Aires, Argentina., Rodríguez-García J; Preventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, University of the Balearic Islands (UIB), Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Mallorca, Balearic Islands, Spain., Mital M; Agnieszka Mital Centrum Badan Klinic, Elblag, Poland., Zala C; Vacunar Sede Las Cañitas, Buenos Aires, Argentina., Pek B; Clinique de Pneumologie et du Sommeil de Lanaudière, Saint-Charles-Borromée, Québec, Canada., Schmitt B; Studienzentrum Mainz Mitte, Mainz, Germany., Toursarkissian N; Praxis Dr. Med. Nicole Toursarkissian, Berlin, Germany., Ochoa Mazarro D; Clinical Pharmacology Department, Hospital Universitario De La Princesa, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain., Großkopf J; Praxis Dr. Med. Josef Großkopf, Wallerfing, Germany., Voors-Pette C; QPS Netherlands B.V, Groningen, The Netherlands., Mehta H; Clinical Research Institute, Minneapolis, MN, USA., Amare Hailemariam H; GSK, Wavre, Belgium., Gérard C; GSK, Rixensart, Belgium., Damaso S; GSK, Wavre, Belgium., David MP; GSK, Wavre, Belgium., Descamps D; GSK, Wavre, Belgium., Hill J; GSK, Wavre, Belgium., Vandermeulen C; GSK, Wavre, Belgium., Hulstrøm V; GSK, Wavre, Belgium.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2579335. Date of Electronic Publication: 2025 Nov 05.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41194599
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immune persistence and safety of the AS01<subscript>E</subscript>-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ferguson+M%22">Ferguson M</searchLink>; Colchester Research Group, Truro, Canada.<br /><searchLink fieldCode="AU" term="%22Schwarz+TF%22">Schwarz TF</searchLink>; Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Núñez+SA%22">Núñez SA</searchLink>; Centro Medico Maffei, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Rodríguez-García+J%22">Rodríguez-García J</searchLink>; Preventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, University of the Balearic Islands (UIB), Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Mallorca, Balearic Islands, Spain.<br /><searchLink fieldCode="AU" term="%22Mital+M%22">Mital M</searchLink>; Agnieszka Mital Centrum Badan Klinic, Elblag, Poland.<br /><searchLink fieldCode="AU" term="%22Zala+C%22">Zala C</searchLink>; Vacunar Sede Las Cañitas, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Pek+B%22">Pek B</searchLink>; Clinique de Pneumologie et du Sommeil de Lanaudière, Saint-Charles-Borromée, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Schmitt+B%22">Schmitt B</searchLink>; Studienzentrum Mainz Mitte, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Toursarkissian+N%22">Toursarkissian N</searchLink>; Praxis Dr. Med. Nicole Toursarkissian, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Ochoa+Mazarro+D%22">Ochoa Mazarro D</searchLink>; Clinical Pharmacology Department, Hospital Universitario De La Princesa, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Großkopf+J%22">Großkopf J</searchLink>; Praxis Dr. Med. Josef Großkopf, Wallerfing, Germany.<br /><searchLink fieldCode="AU" term="%22Voors-Pette+C%22">Voors-Pette C</searchLink>; QPS Netherlands B.V, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mehta+H%22">Mehta H</searchLink>; Clinical Research Institute, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Amare+Hailemariam+H%22">Amare Hailemariam H</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Gérard+C%22">Gérard C</searchLink>; GSK, Rixensart, Belgium.<br /><searchLink fieldCode="AU" term="%22Damaso+S%22">Damaso S</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22David+MP%22">David MP</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Descamps+D%22">Descamps D</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Hill+J%22">Hill J</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Vandermeulen+C%22">Vandermeulen C</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Hulstrøm+V%22">Hulstrøm V</searchLink>; GSK, Wavre, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2579335. <i>Date of Electronic Publication: </i>2025 Nov 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41194599
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2025.2579335
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2579335
    Titles:
      – TitleFull: Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ferguson M
      – PersonEntity:
          Name:
            NameFull: Schwarz TF
      – PersonEntity:
          Name:
            NameFull: Núñez SA
      – PersonEntity:
          Name:
            NameFull: Rodríguez-García J
      – PersonEntity:
          Name:
            NameFull: Mital M
      – PersonEntity:
          Name:
            NameFull: Zala C
      – PersonEntity:
          Name:
            NameFull: Pek B
      – PersonEntity:
          Name:
            NameFull: Schmitt B
      – PersonEntity:
          Name:
            NameFull: Toursarkissian N
      – PersonEntity:
          Name:
            NameFull: Ochoa Mazarro D
      – PersonEntity:
          Name:
            NameFull: Großkopf J
      – PersonEntity:
          Name:
            NameFull: Voors-Pette C
      – PersonEntity:
          Name:
            NameFull: Mehta H
      – PersonEntity:
          Name:
            NameFull: Amare Hailemariam H
      – PersonEntity:
          Name:
            NameFull: Gérard C
      – PersonEntity:
          Name:
            NameFull: Damaso S
      – PersonEntity:
          Name:
            NameFull: David MP
      – PersonEntity:
          Name:
            NameFull: Descamps D
      – PersonEntity:
          Name:
            NameFull: Hill J
      – PersonEntity:
          Name:
            NameFull: Vandermeulen C
      – PersonEntity:
          Name:
            NameFull: Hulstrøm V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1